DOXORUBICIN HYDROCHLORIDE

LOE Approaching

doxorubicin hydrochloride

NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10

Mechanism of Action

hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and…

Clinical Trials (5)

NCT04874311Phase 2Recruiting

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Started Mar 2022
80 enrolled
Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma
NCT02648477Phase 2Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Started Mar 2016
30 enrolled
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
NCT01636947Phase 4Completed

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Started Dec 2012
494 enrolled
NauseaVomiting
NCT01189253Phase 2/3Terminated

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Started May 2011
133 enrolled
Sarcoma
NCT01371227Phase 1Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Started Apr 2011
3 enrolled
Multiple Myeloma